Found 8 matching trials
Phase I Study of Recombinant Human IL-15 (rhIL-15) and Mogamulizumab for People With Refractory or Relapsed Adult T-Cell Leukemia and Mycosis Fungoides/Sezary Syndrome PHASE1 Background:
Adult T-cell leukemia/lymphoma (ATLL) and mycosis fungoides/Se...
Show More Location
National Institutes of Health Clinical Center
Learn More & Join Trial
Haploidentical Donor Natural Killer Cell Infusion With IL-15 in Acute Myelogenous Leukemia (AML) PHASE1 This is a single center, "modified standard design" dose escalation study d...
Show More Location
Masonic Cancer Center, University of Minnesota
Learn More & Join Trial
A Phase I Study of Intravenous Recombinant Human IL-15 in Adults With Refractory Metastatic Malignant Melanoma and Metastatic Renal Cell Cancer PHASE1 Background:
* Recombinant human interleukin-15 (rhIL-15) is a substance th...
Show More Location
National Institutes of Health Clinical Center, 9000 Rockville Pike
Learn More & Join Trial
Avelumab (Bavencio) With IL-15 in Subjects With Clear-Cell Renal Carcinoma PHASE2 Background:
-Clear-cell renal cell carcinoma (ccRCC) is a kind of kidney c...
Show More Location
National Institutes of Health Clinical Center
Learn More & Join Trial
Interleukin-15 (IL-5) in Combination With Avelumab (Bavencio) in Relapsed/Refractory Mature T-cell Malignancies PHASE1 Background:
Some T-cell lymphomas and leukemias do not respond to standard...
Show More Location
National Institutes of Health Clinical Center
Learn More & Join Trial
Continuous Infusion of rhIL-15 for Adults With Advanced Cancer PHASE1 Background:
\- People with cancer can have a weak immune system as a resul...
Show More Location
National Institutes of Health Clinical Center, 9000 Rockville Pike
Learn More & Join Trial
Human IL-15 (rhIL-15) and Obinutuzumab for Relapsed and Refractory Chronic Lymphocyte Leukemia PHASE1 Background:
Chronic lymphocytic leukemia (CLL) is a blood cancer. Recombin...
Show More Location
National Institutes of Health Clinical Center
Learn More & Join Trial
Recombinant Interleukin-15 in Combination With Checkpoint Inhibitors Nivolumab and Ipilimumab in People With Refractory Cancers PHASE1 Background:
The drug Interleukin-15 (IL-15) activates the immune system. T...
Show More Location
National Institutes of Health Clinical Center
Learn More & Join Trial